Patents by Inventor Oleksandr LEVENETS

Oleksandr LEVENETS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Urea derivatives and methods of use thereof
    Patent number: 11345669
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 31, 2022
    Assignee: NodThera Limited
    Inventors: David Harrison, Alan Paul Watt, Nicolas Boutard, Charles-Henry Fabritius, Michal Galezowski, Piotr Kowalczyk, Oleksandr Levenets, Jakub Woyciechowski
  • SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
    Publication number: 20210087147
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 25, 2021
    Inventors: Mark G. BOCK, David HARRISON, Alan Paul WATT, Roderick Alan PORTER, Nicolas Felix Pierre BOUTARD, Charles-Henry Robert Yves FABRITIUS, Grzegorz Witold TOPOLNICKI, Oleksandr LEVENETS
  • CHEMICAL COMPOUNDS
    Publication number: 20200131141
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: March 12, 2018
    Publication date: April 30, 2020
    Inventors: David HARRISON, Alan Paul WATT, Nicolas BOUTARD, Charles-Henry FABRITIUS, Michal GALEZOWSKI, Piotr KOWALCZYK, Oleksandr LEVENETS, Jakub WOYCIECHOWSKI
  • PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS
    Publication number: 20180265467
    Abstract: The present invention relates to pyrazolidine derivatives and related compounds, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of such compounds and pharmaceutical compositions for the prophylaxis and treatment of medical conditions that can be affected by inhibiting lactate dehydrogenase (LDH), in particular LDHA and/or LDHB.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 20, 2018
    Applicant: SELVITA S.A.
    Inventors: Michal GALEZOWSKI, Andrzej GONDELA, Oleksandr LEVENETS, Joanna FOGT, Lukasz DUDEK, Alicja OBARA, Jakub WOYCIECHOWSKI, Marta SOWINSKA, Marcin KROL, Artur BIELA, Tomasz RSYMSKI